Discover Great Companies Discover Great Clients
Popularity  6.6万   |   Followers  21   |   Likes  35   |   Feedback  12 Claim this company

An enterprise engaged in R&D and industrialization of recombinant prot

No.840 Beijing Popularity Ranking No.93 Yizhuang Development Zone No.1 GMP Production No.3 Chong Zu Dan Bai No.4 Kang Ti Yao No.5 Dan Ke Long Kang Ti No.5 Dan Ke Long Kang Ti Yao Products No.5 Fen Zi Sheng Wu Xue No.6 Ren Yong Yi Miao No.6 Vaccines Technology No.6 Vaccines No.7 Hoisting Chain Strip No.7 Antibodies No.10 Yao Li Yan Jiu 院士工作站 理事单位 高新技术企业 知识产权试点企业 中关村高新技术企业 科技型中小企业
More

Company Overview

  • Nature: Private Enterprise Size: 1000-4999 employees Founded: 24年
  • Industry: Pharmaceutical/Bioengineering 、 Raw material processing 、 Academic/Scientific research
  • Full name: Sinocell Engineering Co., Ltd.。

Development Stage

  • Ranking: Ranked #840 in Beijing by popularity Ranked #1 in Beijing GMP Production Company by popularity Ranked #3 in Beijing Chong Zu Dan Bai Company by popularity Ranked #4 in Beijing Kang Ti Yao Company by popularity Ranked #5 in Beijing Dan Ke Long Kang Ti Company by popularity
  • Honors: 院士工作站 理事单位 According to algorithm
  • Salary: 87.1% of positions earn 10-30K, In 2026 vs last yeargrew by 3%.。Master's salary: ¥28.0K, Doctorate salary: ¥31.4K.
  • R&D: "Medical & Health/Beauty & Healthcare" demand: 36.7%, "Biology/Pharmaceutical/Chemical/Environmental Protection": 23.1%, "Other (R&D and Technical)": 5.3%。
  • Recruiting: In 2026 vs 2025grew by 11%. Demand for highly educated talent: Master's: 22, Doctorate: 10.
  • Requirement: Education: 大专 leads with 61.2%. Experience: 不限 leads with 38.1%.
  • Region: Distributed across 31 regions, 北京: 28.9%, 武汉: 3.8%, 上海: 3.5%, 济南: 3.1%.

About the Company

[Summary] An enterprise engaged in R&D and industrialization of recombinant prot

Beijing Sinocell Biotech Group Co., Ltd. is an innovative biopharmaceutical R&D company founded by Dr. Xie Liangzhi, an internationally renowned expert in biopharmaceutical R&D and industrialization, and a member of the expert panel for the Major New Drug Creation Program. The company focuses on the R&D and industrialization of biological drugs such as monoclonal antibodies, recombinant proteins, and vaccines. Since the establishment of the group's subsidiary Sinocell Engineering Co., Ltd. in 2002, the company has been committed to establishing a leading technology platform for biopharmaceutical R&D and production with advanced technical level and cost advantages through innovation in life sciences and engineering, to solve technical bottlenecks in drug R&D and production, and to provide high-quality biological drugs that are affordable to the public at an economic cost, thereby improving the accessibility of high-end biological drugs for patients in China and developing countries. At the same time, the company is committed to developing innovative biological drugs with differentiated competitive advantages in clinical practice, such as Best-in-Class or 'Me-better' products, to achieve the goal of entering developed markets in Europe and the United States with domestically developed and produced biological drugs, benefiting patients worldwide, and establishing an internationally leading biopharmaceutical brand. The company's management team has extensive experience in biological drug R&D and production. During his doctoral studies at the Massachusetts Institute of Technology, the founder Dr. Xie Liangzhi pioneered a stoichiometrically controlled fed-batch culture process for animal cells and increased antibody production from 50 mg/L to 2,400 mg/L in 1994, laying an important foundation for large-scale production of antibody drugs. After returning to China in 2002, he undertook several national '863' projects and major special projects for 'New Drug Creation'; led the team to establish an internationally first-class technology platform for biological drug R&D and industrialization, breaking through a series of key technologies and overcoming difficult drug production processes such as recombinant coagulation factor VIII, long-acting interferon-beta, and 14-valent HPV vaccines. The company's deputy general manager, Dr. Wang Yang, has over 20 years of experience in vaccine and antibody drug R&D and project management, and has led the quality analysis and establishment of quality standards for cervical cancer vaccines; she is an internationally renowned expert in biological drug quality control. On June 22, 2020, the company publicly issued shares for the first time and was listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange.

Expand
Information is aggregated from the web and may not be exact. For reference only.
Information incorrect? Claim this company to edit

Sinocell Engineering How Fast Is Hiring Growing? (97 open positions)

Manage
?
Growth Rate
2026 vs 2025
  • 2025: Up 71%
  • 2024: Up 19%
  • 2023: Down 14%
  • 2022: Up 98%
Sinocell Engineering Year-by-Year Hiring:
* Hiring was generally low during 2020-2022 due to the pandemic
Sinocell Engineering Campus Recruitment & Advanced Degree Talent Demand
Graduates 1 Master's 22 Doctorate 10
Note: How fast is hiring at Sinocell Engineering Co., Ltd. growing? Sinocell Engineering2026: 613 openings (up 11%), 2025: 551 openings (up 71%), 2024: 322 openings (up 19%), 2023: 271 openings (down 14%), 2022: 315 openings (up 98%), 2021: 159 openings. A rising curve may indicate expansion; a falling curve may indicate slower growth or good retention. Based on publicly available data, for reference only.

Sinocell Engineering Master's Degree Job Demand Analysis

(More)
How fast is master's hiring at Sinocell Engineering Co., Ltd. growing? . Sinocell Engineering master talent ranking in Beijing: #263, Sinocell Engineering master salary mostly around 20-50K.

Sinocell Engineering Doctoral Degree Job Demand Analysis

(More)
+62%
Growth Rate
2026 vs 2025
  • 2025: Up 8%
  • 2024: Down 45%
  • 2023: Down 21%
  • 2022: Up 33%
Sinocell Engineering Doctoral Hiring by Year: 2026 — 8 more jobs than 2025
* Hiring was generally low during 2020-2022 due to the pandemic
How fast is doctoral hiring at Sinocell Engineering Co., Ltd. growing? Sinocell EngineeringDoctorate recruitment over the years: 2026: 21 openings (up 62%), 2025: 13 openings (up 8%), 2024: 12 openings (down 45%), 2023: 22 openings (down 21%), 2022: 28 openings (up 33%), 2021: 21 openings. Sinocell Engineering doctorate talent ranking in Beijing: #70, Sinocell Engineering doctorate salary mostly around 20-50K.

Sinocell Engineering R&D Strength (Technical Talent Demand)

(More)
How is the demand for technical talent at Sinocell Engineering Co., Ltd.? Based on an analysis of Sinocell Engineering's job postings over the past year, "Medical & Health/Beauty & Healthcare" demand: 36.7%, "Biology/Pharmaceutical/Chemical/Environmental Protection": 23.1%, "Other (R&D and Technical)": 5.3%, "Scientific Research": 4.4%, "Computer/Network/Technology": 2.8%. For reference only.

Sinocell Engineering — What Are the Salaries Like? (683 records)

Manage
salary range: 6K - 50K, 87.1% of roles pay ¥10-30K
Note: salary statistics are based on 683 salary records from the past year and depend on the job sample. For reference only.
How is the salary at Sinocell Engineering Co., Ltd.?Sinocell Engineering87.1% of positions earn 10-30K, Fresh graduate salary: ¥16.9K。Beijing salary ranking: #4217,销售类 average salary ¥15.6K。 Note: Based on analysis of job postings, does not represent current on-the-job positions; system stability may affect objectivity. For reference only.Data inaccurate? Let us know

Salaries for hot jobs of Sinocell Engineering

(More)
Are salaries high at Sinocell Engineering Co., Ltd.? We provide: Pharmaceutical Sales Representative, pd, 临床, ra, Regional Manager, Researcher, Sales, Senior Manager, 医学经理, Medical Science Liaison, 实验员, Product Manager, Analyst, 药物警戒, Programmer, 计算机辅助药物设计, cad, Production Manager, 监察, Project Manager. Click to view detailed salary analysis by job.

Sinocell Engineering honors, qualifications & industry associations

Tags are labelled based on keyword text matching analysis and may be related to the company. For reference only.

Job Category

  • 销售类
    64.2% of total 64.2%
  • 医疗卫生/美容保健类
    36.8% of total 36.8%
  • 生物/制药/化工/环保类
    23.1% of total 23.1%
  • 经营管理类
    10.8% of total 10.8%

Education

  • 大专
    61.2% of total 61.2%
  • 本科
    21.2% of total 21.2%
  • 硕士
    12.4% of total 12.4%
  • 博士
    3.2% of total 3.2%

Experience

  • 不限
    38.1% of total 38.1%
  • 1-3年
    30.4% of total 30.4%
  • 3-5年
    21.6% of total 21.6%
  • 5-10年
    9.3% of total 9.3%
View Detailed Analysis

What does Sinocell Engineering Co., Ltd. require? Who is Sinocell Engineering hiring? Sinocell Engineering recruitment: 销售类占比最多占64.2%,其次是医疗卫生/美容保健类占36.8%. What education can get in at Sinocell Engineering? 大专占比最多占61.2%,其次是本科占21.2%. High education required at Sinocell Engineering? 硕士占12.4%,博士占3.2%. Work experience required at Sinocell Engineering? 不限占比最多占38.1%,其次是1-3年占30.4%. Where are the job locations at Sinocell Engineering? 北京占比最多占28.9%,其次是武汉占3.8%. Based on job postings from the past year, for reference only.

Business Registration

Provided by

Operating Status: 开业
Registered Capital: 130,000万(元)
Legal Representative: 谢良志
Date Established:
Credit Code: 91110302740070055D
Registered Address: 北京市北京经济技术开发区科创七街31号院5号楼301室

Partners & Suppliers

为神州细胞提供化学药中间体生产服务 Source
供应商 客户-生物技术公司
生物药非临床安全性评价 Source
供应商 生物制药
为神州细胞提供临床研究服务 Source
供应商 创新生物科技企业
国药股份采购神州细胞的重组八因子用于血友病治疗领域分销 Source
合作客户 生物制品(单抗/重组蛋白)
北京大学第三医院参与神州细胞部分药物的临床试验。 Source
供应商 临床试验服务

People who follow Sinocell Engineering also follow

Sinocell Engineering Competitors (Similar Companies)

“Improving public health”
“Dedicated to the research and development of molecularly targeted drug”
“A leader in China's pharmaceutical and healthcare market”
“A pharmaceutical enterprise with over 70 years of glorious history”
“To develop high-quality biologics that are accessible and affordable f”
医药 医药服务 CRO 临床研究
“Continuously innovating to bring patients medicines that significantly”
“One of the leading enterprises in the pharmaceutical industry”
“Helping partners successfully develop new drugs, reducing R&D costs an”
“The company is primarily engaged in the research and development and p”
“Dedicated to the research, development, production, and commercializat”
“Adhering to the corporate culture of science and excellence, committed”
医药 生物医药 新药研发 CRO
“Large-scale pharmaceutical distribution enterprise”
“Although the processing is complicated, we dare not save labor; althou”

Discover Great Companies, Discover Great Clients

北京公司名录 北京“Yizhuang Development Zone”公司名录 北京“生物科技/生物工程”公司名录 北京“药物研发”公司名录 北京“单克隆抗体药物”公司名录 北京“抗体药”公司名录 北京“重组蛋白”公司名录 附近的公司

Report

*Reason:

Radical political or ideological topics
Advertising or spam
Pornographic or vulgar content
Obscene language or personal attacks
Other

Congratulations, submitted successfully!

Your edit is under review. You will be notified by email within 1 business day.

Submission failed.

Followed successfully. We'll notify you of any company updates.

Help others learn about this company, add my impression of this company»

Log in with the following accounts to save your follows

Followed successfully, we'll notify you of any company updates